- Home
- ADPT
as of 07-02-2026 3:46pm EST
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 2.7B | IPO Year: | 2019 |
| Target Price: | $17.78 | AVG Volume (30 days): | 4.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.13 | EPS Growth: | 63.89 |
| 52 Week Low/High: | $9.96 - $22.80 | Next Earning Date: | 05-05-2026 |
| Revenue: | $276,976,000 | Revenue Growth: | 54.77% |
| Revenue Growth (this year): | 3.98% | Revenue Growth (next year): | 22.72% |
| P/E Ratio: | -163.00 | Index: | N/A |
| Free Cash Flow: | -48945000.0 | FCF Growth: | N/A |
AI-Powered ADPT Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Adaptive Biotechnologies Corporation (ADPT)
Chief Commercial Ofc Imm Med
Avg Cost/Share
$21.14
Shares
154,768
Total Value
$3,271,795.52
Owned After
221,278
SEC Form 4
Chief Commercial Ofc Imm Med
Avg Cost/Share
$21.00
Shares
11,034
Total Value
$231,714.00
Owned After
221,278
SEC Form 4
Director
Avg Cost/Share
$20.18
Shares
52,084
Total Value
$1,051,055.12
Owned After
15,625
SEC Form 4
Chief Commercial Officer, MRD
Avg Cost/Share
$20.50
Shares
5,000
Total Value
$102,500.00
Owned After
406,775
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$18.01
Shares
6,160
Total Value
$110,941.60
Owned After
1,405,898
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$17.37
Shares
100,000
Total Value
$1,737,000.00
Owned After
1,405,898
SEC Form 4
Chief Commercial Officer, MRD
Avg Cost/Share
$19.00
Shares
5,000
Total Value
$95,000.00
Owned After
406,775
SEC Form 4
Chief Commercial Officer, MRD
Avg Cost/Share
$18.00
Shares
11,000
Total Value
$198,000.00
Owned After
406,775
SEC Form 4
Chief People Officer
Avg Cost/Share
$17.49
Shares
39,741
Total Value
$695,070.09
Owned After
250,934
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$13.04
Shares
3,115
Total Value
$40,619.60
Owned After
256,725
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| BENZENO SHARON | ADPT | Chief Commercial Ofc Imm Med | Jun 29, 2026 | Sell | $21.14 | 154,768 | $3,271,795.52 | 221,278 | |
| BENZENO SHARON | ADPT | Chief Commercial Ofc Imm Med | Jun 26, 2026 | Sell | $21.00 | 11,034 | $231,714.00 | 221,278 | |
| GRIFFIN MICHELLE RENEE | ADPT | Director | Jun 25, 2026 | Sell | $20.18 | 52,084 | $1,051,055.12 | 15,625 | |
| BOBULSKY SUSAN | ADPT | Chief Commercial Officer, MRD | Jun 25, 2026 | Sell | $20.50 | 5,000 | $102,500.00 | 406,775 | |
| ROBINS HARLAN S | ADPT | Chief Scientific Officer | Jun 16, 2026 | Sell | $18.01 | 6,160 | $110,941.60 | 1,405,898 | |
| ROBINS HARLAN S | ADPT | Chief Scientific Officer | Jun 15, 2026 | Sell | $17.37 | 100,000 | $1,737,000.00 | 1,405,898 | |
| BOBULSKY SUSAN | ADPT | Chief Commercial Officer, MRD | Jun 11, 2026 | Sell | $19.00 | 5,000 | $95,000.00 | 406,775 | |
| BOBULSKY SUSAN | ADPT | Chief Commercial Officer, MRD | Jun 4, 2026 | Sell | $18.00 | 11,000 | $198,000.00 | 406,775 | |
| LO FRANCIS | ADPT | Chief People Officer | Jun 4, 2026 | Sell | $17.49 | 39,741 | $695,070.09 | 250,934 | |
| PISKEL KYLE | ADPT | Chief Financial Officer | May 18, 2026 | Sell | $13.04 | 3,115 | $40,619.60 | 256,725 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 5, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYFeb 5, 2026 · 100% conf.
1D
+7.32%
$17.68
Act: -4.25%
5D
+16.66%
$19.21
Act: -5.65%
20D
+11.89%
$18.43
Act: -9.90%
8-K
False000147832000014783202026-02-052026-02-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2026
ADAPTIVE BIOTECHNOLOGIES CORPORATION
(Exact name of Registrant as Specified in Its Charter)
Washington
001-38957
27-0907024
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
1165 Eastlake Avenue East Seattle, Washington
98109
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (206) 659-0067 Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, par value $0.0001 per share
ADPT
The NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02
Results of Operations and Financial Condition.
On February 5, 2026, Adaptive Biotechnologies Corporation (the “Company”) issued a press release regarding the Company’s financial results for the quarter and fiscal year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02 and the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
99.1
Press Release dated February 5, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Adaptive Biotechnologies Corporation
Date: February 5, 2026
By:
/s/ Kyle Piskel
Kyle Piskel
Chief Financial Officer
2025 Q4 Q4 2025 Earnings
8-K BUY Jan 12, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYJan 12, 2026 · 100% conf.
1D
+7.32%
$17.68
Act: -4.25%
5D
+16.66%
$19.21
Act: -5.65%
20D
+11.89%
$18.43
Act: -9.90%
8-K
Adaptive Biotechnologies Corp false 0001478320 0001478320 2026-01-12 2026-01-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026
ADAPTIVE BIOTECHNOLOGIES CORPORATION
(Exact name of Registrant as Specified in Its Charter)
Washington
001-38957
27-0907024
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
1165 Eastlake Avenue East Seattle, Washington
98109
(Address of Principal Executive Offices)
(Zip Code) Registrant’s Telephone Number, Including Area Code: (206) 659-0067 Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, par value $0.0001 per share
ADPT
The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On January 12, 2026, Adaptive Biotechnologies Corporation (the “Company”) issued a press release regarding the Company’s financial results for the quarter and year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02 and the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 7.01. Regulation FD Disclosure
The Company is furnishing presentation materials (the “Investor Presentation”) that management intends to use, possibly with modifications, in one or more meetings from time to time with investors, analysts and others. While the Company may elect to update the Investor Presentation in the future, the Company specifically disclaims any obligation to do so. The Investor Presentation is attached as Exhibit 99.2 hereto and incorporated herein by reference. The information in this Item 7.01 and the Investor Presentation attached as Exhibit 99.2 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, nor shall such information be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
99.1
Press Release dated January 12, 2026
99.2
Investor Presentation dated January 12, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Adaptive Biotechnologies Corporation
Date: January 12, 2026
By:
/s/ Kyle Piskel
Kyle Piskel
Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 5, 2025
Q3 2025 Earnings
8-KNov 5, 2025
8-K
False000147832000014783202025-11-052025-11-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2025
ADAPTIVE BIOTECHNOLOGIES CORPORATION
(Exact name of Registrant as Specified in Its Charter)
Washington
001-38957
27-0907024
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
1165 Eastlake Avenue East Seattle, Washington
98109
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (206) 659-0067 Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, par value $0.0001 per share
ADPT
The NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02
Results of Operations and Financial Condition.
On November 5, 2025, Adaptive Biotechnologies Corporation (the “Company”) issued a press release regarding the Company’s financial results for the quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02 and the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
99.1
Press Release dated November 5, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Adaptive Biotechnologies Corporation
Date: November 5, 2025
By:
/s/ Kyle Piskel
Kyle Piskel
Chief Financial Officer
Compare ADPT vs Leading Stocks
See how ADPT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ADPT Adaptive Biotechnologies Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.